Diabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose?
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Diabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose?
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 18, Issue 9, Pages 839-841
Publisher
Informa UK Limited
Online
2017-04-28
DOI
10.1080/14656566.2017.1323878
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Healthcare Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors
- (2016) Amanda M. Farr et al. ADVANCES IN THERAPY
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus
- (2016) Lea Duvnjak et al. Diabetology & Metabolic Syndrome
- Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
- (2016) Ling Li et al. BMJ-British Medical Journal
- Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
- (2016) Ling Li et al. BMJ-British Medical Journal
- Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis
- (2016) Laurent Azoulay et al. JAMA Internal Medicine
- Retrospective Analysis of Long-Term Adherence to and Persistence with DPP-4 Inhibitors in US Adults with Type 2 Diabetes Mellitus
- (2014) Amanda M. Farr et al. ADVANCES IN THERAPY
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison
- (2014) Paul Craddy et al. Diabetes Therapy
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
- (2011) Chrysi Koliaki et al. Diabetes Therapy
- Dipeptidylpeptitase-4 Inhibitors (Gliptins)
- (2010) André J. Scheen CLINICAL PHARMACOKINETICS
- Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
- (2010) André J. Scheen et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations
- (2009) Raffaele Marfella et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started